Humana (HUM)
(Delayed Data from NYSE)
$387.38 USD
-1.51 (-0.39%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $387.35 -0.03 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HUM 387.38 -1.51(-0.39%)
Will HUM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HUM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUM
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
UnitedHealth Group (UNH) Beats Q2 Earnings and Revenue Estimates
HUM: What are Zacks experts saying now?
Zacks Private Portfolio Services
UnitedHealth (UNH) Pre-Q2 Earnings: Healthy Buy or a Wait-&-See?
Company News for Jul 5, 2024
Humana (HUM) Ties Up With PsychArmor for Better Veteran Care
Other News for HUM
Should You Buy Humana Stock Right Now? Here’s What Piper Sandler Expects
Dividend Champion, Contender, And Challenger Highlights: Week Of July 21
Class Action Lawsuit Against Humana Inc. (NYSE:HUM)
Humana Accelerates Commitment to Helping Seniors Choose Right Health Plan, Announces Minority Investment in Healthpilot
Healthcare Investors Bet On Easier Medicare Rules Under Potential Trump Administration